Lung cancer
To successfully develop novel ways of identifying Indian patients that are likely to benefit from immunotherapy for lung cancer
Who can joinAdults
Age18–75 years
Kind of studyObservational: no new treatment
What it testsWatches and records only
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial HospitalMumbai, MaharashtraDirections ↗
Registry summary (technical)
Developing precision immunotherapy for value-based treatment of lung cancer in India
Sponsor: Emory Vaccine Centre
CTRI/2022/05/042559 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 27 Apr 2026 · read by us 5 Nov 2026